ArticleScientific reports2021
Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 47 citations in OpenAlex.
- Affibody Complex Formation: An In-Depth Thermodynamic Analysis Using Isothermal Titration Calorimetry.Molecules (Basel, Switzerland) · 2026Article
- Combining bacterial display and protein language models to engineer a CD69-binding affibody for molecular imaging of immune activation.Protein engineering, design & selection : PEDS · 2026Article
- Recent Progress on Affibody-Based Supramolecular Architectures: Moving from Monomeric Constructs to Multivalent Assemblies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Engineering high-efficiency matriptase substrates using E. coli display for applications in prodrug activation.Cell reports methods · 2025Article
- DGCR2 targeting affibody molecules for delivery of drugs and imaging reagents to human beta cells.Scientific reports · 2025Article
- Surface-engineered bacteria in drug development.Microbial biotechnology · 2024Review
- Recombinant and Synthetic Affibodies Function Comparably for Modulating Protein Release.Cellular and molecular bioengineering · 2024Article
- Making the effect visible - OX40 targeting nanobodies forFrontiers in immunology · 2024Article
- Moderate-Affinity Affibodies Modulate the Delivery and Bioactivity of Bone Morphogenetic Protein-2.Advanced healthcare materials · 2023Article
- Identification and validation of CCL2 as a potential biomarker relevant to mast cell infiltration in the testicular immune microenvironment of spermatogenic dysfunction.Cell & bioscience · 2023Article
- Imaging of Activated T Cells.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Review
- Novel smallFrontiers in oncology · 2022Article
- PET Imaging for Monitoring Cellular and Immunotherapy of Cancer.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the wide scale of inflammatory processes in different types of disease, more sensitive and specific biomarkers are required to improve prevention and treatment. Cluster of differentiation 69 (CD69) is one of the earliest cell surface proteins expressed by activated leukocytes. Here we characterize and optimize potential new imaging probes, Affibody molecules targeting CD69 for imaging of activated immune cells. Analysis of candidates isolated in a previously performed selection from a Z variant E. coli library to the recombinant extracellular domain of human CD69, identified one cross-reactive Z variant with affinity to murine and human CD69. Affinity maturation was performed by randomization of the primary Z variant, followed by selections from the library. The resulting Z variants were evaluated for affinity towards human and murine CD69 and thermal stability. The in vivo biodistribution was assessed by SPECT/CT in rats following conjugation of the Z variants by a DOTA chelator and radiolabeling with Indium-111. A primary Z variant with a K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.